Wells Fargo Downgrades Chinook Therapeutics to Equal-Weight, Raises Price Target to $40
Portfolio Pulse from richadhand@benzinga.com
Wells Fargo analyst Mohit Bansal has downgraded Chinook Therapeutics from Overweight to Equal-Weight, while raising the price target from $30 to $40.
August 01, 2023 | 10:29 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Chinook Therapeutics has been downgraded by Wells Fargo from Overweight to Equal-Weight, but the price target has been raised from $30 to $40.
The downgrade from Overweight to Equal-Weight suggests that Wells Fargo sees less potential for outperformance in Chinook Therapeutics' stock. However, the raised price target from $30 to $40 indicates that the analyst still sees upside potential, which could balance out the impact of the downgrade.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100